Metamizole sodium (analgin) veterinary grade is a water-soluble pyrazolone derivative released as a white to almost white crystalline powder. Input API release is governed by the current European Pharmacopoeia monograph for metamizole sodium monohydrate, where applicable, and residual solvent assessment under VICH GL18. The API is processed into finished dosage forms only in markets where the active substance is approved for the target species; food-producing animal applications require verification of maximum residue limit status, withdrawal period data and national listing status before formulation, because the regulatory status of metamizole is not harmonized across jurisdictions. The downstream scenarios are separated by manufacturing route and are limited to real processing platforms: sterile injectable liquid, water-dispersible oral powder, tablet compression, capsule filling, granulation/feed premix dilution and oral solution. Each scenario defines the compliance anchor, active loading ratio, production-scale process sequence and terminal article type. Unless otherwise noted, formulation percentages are representative starting points for development and must be validated on the specific installed equipment.

In water-dispersible powder processing, a 500 mg/g formulation is selected when mass medication of pigs or poultry through drinking water is authorized in the target jurisdiction. The active addition ratio is fixed at 50.0% w/w on an anhydrous basis, with the carrier split between anhydrous dextrose at 40.0–45.0% w/w, citric acid at 1.0–2.0% w/w as a sequestrant and colloidal silicon dioxide at 0.5–1.0% w/w as a moisture scavenger. Manufacturing is conducted under ICH Q7 non-sterile conditions; blend uniformity is assessed by Ph. Eur. 2.9.40, and loss on drying is controlled by Ph. Eur. 2.2.32 with a limit of ≤2.0% w/w. In production-scale processing, the API is first sieved through a 710 µm stainless steel screen and geometrically diluted in a 2,000 L double-ribbon blender operated at 12–15 rpm for 20–25 min; a two-stage pre-blend is used because the API can adhere to polypropylene internal surfaces at relative humidity below 30%. Packaging is performed at 30–40% RH and 18–22°C into 100 g, 500 g and 1 kg four-layer aluminium/polyethylene sachets; 25 kg foil-lined bulk drums are filled for licensed repackaging. The process boundary is moisture pickup during filling: residual moisture above 2.5% w/w after packaging can initiate agglomeration and darkening in the presence of reducing sugar carriers.

What Limits Aseptic Filling Line Speed for 500 mg/mL Injectable Solutions?

Sterile injectable presentation requires dissolution of metamizole sodium at a final loading of 50.0% w/v, equivalent to 500 mg/mL, in water for injection at 18–25°C. The pH is adjusted to 6.0–7.5 with 0.1 M sodium hydroxide or hydrochloric acid; for multi-dose containers, benzyl alcohol is incorporated at 0.5–1.0% v/v only after preservative efficacy testing is completed. The solution is blanketed with nitrogen and filtered through a 0.22 µm double-filter train immediately before aseptic filling; terminal steam sterilization is avoided because aqueous metamizole sodium is sensitive to hydrolytic degradation and oxidative discoloration under elevated heat. Compliance anchors for this route include EU GMP Annex 1, Ph. Eur. 2.6.1 for sterility, Ph. Eur. 2.6.14 for bacterial endotoxins, USP <788> for particulate matter and VICH GL18 where residual solvents must be reported. Production equipment consists of a 316L stainless steel mixing vessel with a 0.2–0.5 bar nitrogen overlay, ceramic or polyethersulfone capsule filters and a linear aseptic filling line with peristaltic pumps; fill volume tolerance is ±1.0% of label claim. Line speed is held at 80–120 vials/min because the low-viscosity solution can foam under pump transfer and oxidative discoloration can occur if the solution is held under high-shear conditions. Terminal articles are 50 mL, 100 mL and 250 mL Type I borosilicate glass vials with bromobutyl rubber stoppers and light-protective cartons. The filled solution must be stored below 25°C and protected from direct sunlight; freezing is not recommended because crystallization can occur in high-concentration solutions.

When direct compression is applied to 500 mg metamizole sodium tablet cores for companion animal therapy, a fill weight of 750 mg with an active loading of 66.7% w/w is used. The qualitative formulation contains microcrystalline cellulose PH 102 at 20.0% w/w, lactose monohydrate at 8.0% w/w, sodium starch glycolate at 3.0% w/w, colloidal silicon dioxide at 0.8% w/w and magnesium stearate at 1.5% w/w. Compliance is assessed under ICH Q7; dosage unit uniformity is evaluated by Ph. Eur. 2.9.40, disintegration by Ph. Eur. 2.9.1 with a limit of ≤15 min in water at 37±2°C, and friability by Ph. Eur. 2.9.7 with a limit of ≤1.0%. The production sequence begins with API pre-sieving through a 0.85 mm mesh, followed by blending in a 600 L bin blender at 8 rpm for 15 min; magnesium stearate is added during the final 3 min to limit over-lubrication and disintegration delay. Tablets are compressed on a 27-station rotary press with 19.0 mm × 8.5 mm oval punches at a main compression force of 12–18 kN and press speed of 35–50 rpm; core hardness is monitored at 70–120 N and friability is checked in-line. Operation above 55% RH at the press outlet increases edge chipping and weight variation. Terminal packs are PVC/PVDC-Alu blisters containing 10 or 100 tablets. A process boundary is press speed above 60 rpm without pre-slugging, because the high active loading reduces compaction dwell time and produces capping.

When Hard Gelatin Capsules Are Selected Over Tablets in Compounded Companion Animal Pack-Outs

Capsule filling is adopted when the veterinary product requires lower unit dose strength or when tablet tooling changeover is not economical for small-batch production. A size 0 capsule containing 250 mg metamizole sodium uses a fill powder with active loading of 40–60% w/w, lactose monohydrate at 35–55% w/w, croscarmellose sodium at 2–5% w/w and colloidal silicon dioxide at 0.5–1.0% w/w; the total fill mass is 500 mg. Compliance for capsule filling includes ICH Q7, uniformity of dosage units by Ph. Eur. 2.9.40, and dissolution by a compendial paddle method at 50 rpm in 900 mL of pH 6.8 phosphate buffer at 37°C, with a typical acceptance criterion of Q ≥75% at 45 min. On production scale, a dosator-type capsule filler operates at 20,000–30,000 capsules/h in a room held at 20–23°C and 35–45% RH; empty gelatin capsules are equilibrated to 13–16% moisture before filling. Terminal articles are size 0 and size 1 capsules in PVC/PVDC-Alu or Alu-Alu blister formats. The critical incompatibility is aldehyde-containing desiccants or cleaning residues, which induce gelatin cross-linking and dissolution failure; bulk powder storage above 50% RH also increases fill weight drift and shell softening.

Granulated metamizole sodium for oral top-dress and feed premix manufacture is prepared when dry powder dusting during sachet filling or feed mixing must be reduced. The granulated intermediate is loaded at 200 mg/g active, corresponding to 20.0% w/w; the dry formulation includes lactose monohydrate at 65.0% w/w, microcrystalline cellulose at 14.0% w/w and sodium starch glycolate at 1.0% w/w, with a binder solution of povidone K30 at 5.0% w/w in purified water added at 15–20% of dry mass. Compliance for the feed premix segment is governed by Regulation (EC) No 183/2005, FAMI-QS and applicable national medicated feed authorizations; active content is determined by stability-indicating HPLC validated according to ICH Q2(R1), and residual moisture after drying is controlled by Ph. Eur. 2.2.32 at ≤2.5% w/w. The process path uses a 600 L high-shear granulator with impeller speed of 200 rpm and chopper speed of 1,500 rpm, followed by fluid-bed drying at inlet 60–65°C and product temperature 30–35°C; the dried granulate is sieved through a 1.0 mm screen, blended with glyceryl behenate at 0.5% w/w and packed at 30–40% RH. Terminal product types include 10 g oral granule sachets and 20 kg feed premix bags; the premix is diluted at the feed mill according to the approved mg/kg bodyweight dose rather than a fixed final feed inclusion percentage. The operational boundary is pelleted feed production after steam conditioning above 65°C, which is not recommended because thermal exposure above this range can reduce active content; published data for this specific configuration is limited.

Oral Solution pH Drift and Preservative Partitioning in Multi-Dose Bottles

Multi-dose oral solutions require a preservative-protected formula at an active loading of 20.0% w/v, equivalent to 200 mg/mL. The formulation contains potassium sorbate at 0.10–0.15% w/w, sodium benzoate at 0.05–0.10% w/w, citric acid/sodium citrate buffer to pH 6.0–7.0, glycerin at 10.0% w/v and purified water q.s.; the API is dissolved under low-shear agitation at 150–200 rpm in a 316L stainless steel vessel. Compliance anchors include ICH Q7, Ph. Eur. 5.1.3 for preservative efficacy and compendial packaging suitability testing for polymer containers. The production process includes filtration through a 0.45 µm polypropylene cartridge, filling into 1 L HDPE bottles with child-resistant closures at 25–30°C and nitrogen headspace flushing before capping; fill volume tolerance is ±1.5%. Terminal articles are 200 mg/mL oral solution in 500 mL and 1 L HDPE bottles with dosing reservoirs. The operational boundary is pH drift above 8.0 during storage; the methanesulfonate group is susceptible to alkaline hydrolysis, and citrate buffer capacity is not sufficient when the solution is diluted with hard water above 250 ppm calcium carbonate. Long-term storage above 25°C or direct ultraviolet exposure accelerates discoloration and must be excluded by stability validation.